...
首页> 外文期刊>Journal of pharmaceutical sciences. >Drug-Drug Interaction Between Oxycodone and Adjuvant Analgesics in Blood-Brain Barrier Transport and Antinociceptive Effect
【24h】

Drug-Drug Interaction Between Oxycodone and Adjuvant Analgesics in Blood-Brain Barrier Transport and Antinociceptive Effect

机译:羟考酮和辅助镇痛药在血脑屏障转运中的药物相互作用和抗伤害感受作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To examine possible blood-brain barrier (BBB) transport interactions between oxycodone and adjuvant analgesics, we firstly screened various candidates in vitro using [3H]pyrilamine, a substrate of the oxycodone transporter, as a probe drug. The uptake of [3H]pyrilamine by conditionally immortalized rat brain capillary endothelial cells (TR-BBB13) was inhibited by antidepressants (amitriptyline, imipramine, clomipramine, amoxapine, and fiuvoxamine), antiarrhythmics (mexi-letine, lidocaine, and flecainide), and ketamine. On the other hand, antiepileptics (carbamazepine, phenytoin, and clonazepam) and corticosteroids (dexamethasone and prednisolone) did not inhibit [sH]pyrilamine uptake, with the exception of sodium valproate. The uptake of oxycodone was significantly inhibited in a concentration-dependent manner by amitriptyline, fiuvoxamine and mexiletine with Ki values of 13, 65, and 44 |jlM, respectively. These Ki values are 5-300 times greater than the human therapeutic plasma concentrations. Finally, we evaluated in vivo interaction between oxycodone and amitriptyline in mice. Antinociceptive effects of oxycodone were increased by coadministration of amitriptyline. The oxycodone concentrations in plasma and brain were not changed by coadministration of amitriptyline. Overall, the results suggest that several adjuvant analgesics may interact with the BBB transport of oxycodone at relatively high concentrations. However, it is unlikely that there would be any significant interaction at therapeutically or pharmacologically relevant concentrations. ?2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci
机译:为了检查羟考酮和辅助镇痛药之间可能的血脑屏障(BBB)转运相互作用,我们首先使用羟考酮转运蛋白的底物[3H]吡拉明作为探针药物在体外筛选了各种候选药物。有条件的永生化大鼠脑毛细血管内皮细胞(TR-BBB13)对[3H]吡拉明的吸收被抗抑郁药(阿米替林,丙咪嗪,氯米帕明,阿莫沙平和氟乙胺),抗心律不齐药物(甲氧西汀,利多卡因和氟卡尼)抑制,以及氯胺酮。另一方面,除丙戊酸钠外,抗癫痫药(卡马西平,苯妥英钠和氯硝西am)和皮质类固醇(地塞米松和泼尼松龙)均不抑制[sH]吡拉明的摄取。阿米替林,氟乙草胺和美西律以浓度依赖性方式显着抑制羟考酮的摄取,其Ki值分别为13、65和44μlM。这些Ki值是人类治疗性血浆浓度的5-300倍。最后,我们评估了羟考酮和阿米替林之间的体内相互作用。联合使用阿米替林可提高羟考酮的抗伤害作用。并用阿米替林不会改变血浆和大脑中的羟考酮浓度。总体而言,结果表明,几种辅助镇痛药可能与相对较高浓度的羟考酮的BBB转运相互作用。但是,在治疗或药理学相关浓度下不可能发生任何显着的相互作用。 2009 Wiley-Liss,Inc.和美国药剂师协会J Pharm Sci

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号